Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other brokerages also recently commented on MAZE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Stock Down 1.8%

Shares of NASDAQ MAZE opened at $27.18 on Friday. The firm has a market cap of $1.51 billion, a P/E ratio of -10.79 and a beta of 2.21. The company has a debt-to-equity ratio of 0.09, a quick ratio of 17.88 and a current ratio of 18.31. Maze Therapeutics has a 1 year low of $12.81 and a 1 year high of $53.65. The firm’s 50 day moving average price is $27.79 and its 200 day moving average price is $33.03.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). As a group, sell-side analysts anticipate that Maze Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity

In related news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This trade represents a 59.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 140,674 shares of company stock valued at $3,904,707 in the last ninety days. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Hhlr Advisors LTD. acquired a new stake in Maze Therapeutics during the 2nd quarter worth approximately $10,922,000. Jupiter Topco LLC acquired a new position in Maze Therapeutics during the second quarter valued at approximately $101,764,000. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the second quarter valued at approximately $122,983,582,000. ADAR1 Capital Management LLC purchased a new stake in Maze Therapeutics during the second quarter worth approximately $10,124,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Maze Therapeutics in the second quarter worth $272,000.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.